The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Volume 127 , Issue 9
Showing 1-11 articles out of 11 articles from the selected issue
Seminar for Medical Education
Original Articles
  • Tomoyo Sawada, Takashi Matsushita, Yasuhito Hamaguchi, Kazuhiko Takeha ...
    2017 Volume 127 Issue 9 Pages 2097-2104
    Published: August 20, 2017
    Released: August 22, 2017

    Using anti-SRP antibody, we examined the clinical features of 3 cases of dermatomyositis who visited our hospital. The average age of these 3 patients was 57 years and all the cases were female. All 3 patients had Gottron's sign on their hands as a common skin manifestation. They all suffered from muscle weakness and the myogenic enzymes, creatine kinase and aldolase were elevated. Interstitial lung disease and a malignant tumor were each found in 1 of the 3 cases. One patient was treated solely systemic administration of corticosteroid and the remaining 2 patients received a combination therapy of corticosteroid and an immunosuppressive agent. All their symptoms were resolved, and their conditions came under control.

    Download PDF (1047K)
  • Miho Koumura, Masanari Kodera, Yuta Yoshii, Yuki Tsurumi, Yoshihito Ta ...
    2017 Volume 127 Issue 9 Pages 2105-2110
    Published: August 20, 2017
    Released: August 22, 2017

    We report a 35-years-old Japanese female patient suffering from granulomatosis with polyangiitis (GPA). She had orbital granuloma and lung nodules, and she lost her eyesight in the right eye. She was treated for GPA with oral prednisolone and cyclophosphamide. She went into remission; however, she relapsed four months later. We decided to start additional treatment using rituximab, and she went into remission again. After 8 months, her titer of PR3-ANCA rose, and, a month later, we detected CD20 positive B cells, so we started a second course of treatment with rituximab. Although the effectiveness of rituximab for refractory ANCA-associated vasculitis has recently been reported, the details of rituximab maintenance therapy remain unclear.

    Download PDF (1131K)